Generate a tailored SOP for Dr. Alex Dyson. Improve your application with a focused, well-structured draft.
Alex graduated with a BSc in Biology and an MSc in Pharmacology from the University of Hull and the University of Hertfordshire, respectively. He joined Novartis’ Chronic Pain Unit as a Research Associate in 2001. In 2005, he undertook a capacity-building PhD studentship in vivo physiology and pharmacology at University College London, during which he partnered with industry to work on novel oxygen sensors as early indicators of organ hypoperfusion. Following a post-doctoral role at UCL in 2010, he discovered a novel agent for ischaemia/reperfusion injury and subsequently explored spin-out opportunities with Magnus Life Science. In 2014, Alex directed a subsidiary, Magnus Oxygen, continuing his work back at UCL. Since 2017, he has been at the Institute of Pharmaceutical Science at King’s College London, where he established his research group, focusing on chalcogens like oxygen, sulfides, and selenides as related mediators in a broad, multidisciplinary research effort. He works to bridge the academia-industry divide and establish a translational arm that develops novel therapeutics for the treatment of oxidative age-related pathologies and continues to advance the field of drug development science.
Institute of Pharmaceutical Science, King's College London • London, UK
Established research group focusing on drug development science and related fields.
Magnus Oxygen • London, UK
Led subsidiary focused on oxygen technology and related therapeutics.
Novartis • United Kingdom
Worked in the Chronic Pain Unit focusing on novel therapeutic approaches.
Requirements are consistent across King's Business School and Social Science & Public Policy departments for standard Master's entries.